Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
  • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
  • B01F23/40—Mixing liquids with liquids; Emulsifying
  • B01F23/41—Emulsifying
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4196—1,2,4-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1277—Preparation processes; Proliposomes
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
  • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
  • B01F23/40—Mixing liquids with liquids; Emulsifying
  • B01F23/41—Emulsifying
  • B01F23/4105—Methods of emulsifying
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
  • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
  • B01F23/40—Mixing liquids with liquids; Emulsifying
  • B01F23/49—Mixing systems, i.e. flow charts or diagrams
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
  • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
  • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions

Definitions

• C ontinuous manufacturing is a process whereby raw materials constantly flow into a process and intermediates or final product constantly flow out.
• processing has been employed m non-pharmaceutical industries and has recently been adopted in some types of pharmaceutical processes such as the synthesis of active pharmaceutical ingredients (APIs) and generation of solid oral dosage forms (tablets, etc.) (Kleinebudde et al. (Eds.), Continuous Manufacturing of Pharmaceuticals, Wiley-VCH, Hoboken 2017; Subramanian, G. (Ed.), Continuous Process in Pharmaceutical Manufacturing, Wiley-VCH, Weinheim 2015).
• APIs active pharmaceutical ingredients
• tablettes solid oral dosage forms
• ATF tangential flow filtration
• SPTFF single pass tangential flow filtration
• Continuous perfusive cell culture has used ATF to support continuous medium exchange with highly concentration suspensions (Castilho, Continuous Animal Cell Perfusion Processes: The First Step Toward Integrated Continuous Manufacturing, m: Subramanian, G. (Ed.), Continuous Process in Pharmaceutical Manufacturing Wiiey-VCH, Weinheim 2015, pp. 115-153; Whrtford, Single-Use Systems Support Continuous Bioprocessing by Perfusion Culture, in: Subramanian, G. (Ed.), Continuous Process in Pharmaceutical Manufacturing, Wiley-VCH, Weinheim 2015, pp. 183-226)
• Tire present invention addresses the need for a continuous manufacturing process for liposomal active pharmaceutical ingredients (liposomal APIs), such as liposomal drug products.
• a method for manufacturing a liposomal API formulation in a continuous manner is provided.
• One embodiment of the method for manufacturing the liposomal API formulation comprises mixing a lipid solution comprising a lipid dissolved in an organic solvent with an aqueous API solution, wherein the lipid solution and aqueous API solution are mixed from two separate streams in an in-line fashion, and wherein a liposomal encapsulated API is formed at the intersection of the two streams.
• the method further comprises introducing the liposomal encapsulated API into a central vessel comprising a first inlet, a second inlet, a first outlet and a second outlet, through the first inlet.
• the first outlet of the central vessel is in fluid communication with an inlet of a first tangential flow filtration (TFF) unit.
• the first TFF unit comprises the aforementioned inlet and a first and second outlet.
• the first outlet of the first TFF unit is in fluid communication with the second inlet of the central vessel and the second outlet of the first TFF unit is a waste outlet.
• the second outlet of the central vessel is in fluid communication with an inlet of a second TFF unit comprising the inlet and a first and second outlet.
• the first outlet of the second TFF unit is a retentate outlet and the second outlet of the second TFF unit is a waste (permeate) outlet.
• the method further comprises continuously flowing the liposomal encapsulated API into the first TFF unit for a first period of time.
• the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the central vessel through the inlet of the second TFF unit for a second period of time and collecting the liposomal API formulation from the first outlet of
• the method comprises flowing the liposomal encapsulated API from the central vessel into one or more additional TFF units prior to flowing tire liposomal API formulation into the second TFF unit.
• the second TFF unit is a single pass TFF unit (SPIFF).
• the method for manufacturing the liposomal API formulation comprises mixing a lipid solution comprising a lipid dissolved in an organic solvent with an aqueous API solution, wherein the lipid solution and aqueous API solution are mixed from two separate streams in an in-line fashion, and wherein a liposomal encapsulated API is formed at the intersection of the two streams.
• the method further comprises introducing the liposomal encapsulated API into a central vessel comprising an inlet and an outlet, through the inlet. Tie outlet is in fluid communication with an inlet of a first tangential flow filtration (IFF) unit.
• the first TFF unit comprises the aforementioned inlet and a first and second outlet.
• the first outlet of the first TFF unit is in fluid communication with the inlet of a second TFF and the second outlet of the first TFF unit is a waste (permeate) outlet.
• the second TFF comprises the aforementioned inlet and a first and second outlet.
• the first outlet of the second TFF unit is a retentate outlet and the second outlet of the second TFF unit is a waste (permeate) outlet.
• the method further comprises continuously flowing the liposomal encapsulated API into the first TFF unit for a first period of time.
• the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the first outlet of the first TFF through the inlet of the second TFF unit for a second period of time and collecting the liposomal API formulation from tire first outlet of the second TFF unit.
• the method comprises flowing the liposomal encapsulated API from the central vessel into one or more additional TFF units prior to flowing the liposomal API formulation into the second TFF unit.
• the second TFF unit is a single pass TFF unit (SPIFF).
• the method for manufacturing a liposomal API formulation comprises mixing a lipid solution comprising a lipid dissolved in an organic solvent with an aqueous API solution, wherein the lipid solution and aqueous API solution are mixed from two separate streams in an in-line fashion, and wherein liposomal encapsulated API is formed at the intersection of the two streams.
• the method further comprises introducing the liposomal encapsulated API into a central vessel comprising a first inlet, a second inlet, a first outlet and a second outlet, through the first inlet.
• Tire first outlet is in fluid communication with an inlet of a first tangential flow filtration (TFF) umt comprising the inlet and a first and second outlet.
• TMF tangential flow filtration
• the first outlet of the first IFF unit is in fluid communication with the second inlet of the first central vessel and the second outlet of the first TFF unit is a waste outlet.
• Tire second outlet of the first central vessel is in fluid communication with a first inlet of a second central vessel.
• the second central vessel comprises the first inlet, a second inlet, a first outlet and a second outlet, and the first outlet of the second central vessel is in fluid communication with an inlet of a second tangential flow filtration (TFF) unit comprising the inlet and a first and second outlet.
• TFF tangential flow filtration
• Tire second outlet of the second central vessel is in fluid communication with an inlet of a third TFF unit comprising the inlet and a first and second outlet, the first outlet of the third TFF unit is a retentate outlet and the second outlet of the third TFF unit is a waste (permeate) outlet.
• the method further comprises continuously flowing the liposomal encapsulated API into the fi rst ' IFF unit for a first period of time, wherein the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the first central vessel into the second central vessel for a second period of time and continuously flowing the liposomal encapsulated API into the second TFF unit from the second central vessel for a third period of time.
• the liposomal encapsulated API enters the second TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the second central vessel through the inlet of the third TFF unit for a fourth period of time; and collecting the liposomal encapsulated API formulation from the first outlet of the third TFF unit.
• the method comprises flowing the liposomal encapsulated API from the second central vessel into one or more additional TFF units prior to flowing the liposomal API formulation into the third TFF unit.
• the third TFF unit is a single pass TFF unit (SPTFF)
• mixing the lipid solution and the aqueous API solution results in the formation of a API coacervate.
• the API coacervate initiates lipid bilayer formation around the API coacervate.
• the API is an aminoglycoside.
• the aminoglycoside is amikacin, or a pharmaceutically acceptable salt thereof.
• the amikacin is amikacin sulfate
• a buffer is introduced into the first central vessel through a third inlet prior to the first period of time or during the first period of time.
• Figure 1 is a liposomal API manufacturing process flow diagram. Ethanol/ether injection batch design method: lipid/solvent solution is directly fed into the central vessel. Formulations are refined in multi-step buffer exchange diafiltration and concentration steps.
• Figure 2 is a liposomal API manufacturing process flow diagram.
• Crossflow method solvent/anti-solvent mix in-line at an intersection point. Formulations are refined in multi-step buffer exchange diafiltration and concentration steps.
• FIG 3 is a process design for continuous liposome API manufacturing.
• Figure 4 is a process design for continuous liposome API manufacturing. Continuous multistage (multi-vessel) buffer exchange TFF and single stage concurrent concentrating SPTFF.
• Figure 5 is a process design for continuous liposome API manufacturing. Single tank buffer exchange TFF and multistage concurrent concentrating SPTFF.
• Figure 6 is a process design for continuous liposome API manufacturing. Multistage buffer exchange (in-line diafiltration (ILDF)) with concurrent concentrating SPTFF.
• ILDF in-line diafiltration
• Figure 7 compares batch vs. continuous processing steps/times for a liposomal API product.
• the present invention in one aspect, relates to the use of continuous manufacturing processes for the manufacture of liposomal API products.
• the potential benefits of implementing a continuous manufacturing process include economic advantages (lower capital expenditures, smaller facility footprint, lower overall cost of goods sold (COGS)), as well as improved consistency and quality of product.
• a liposomal API formulation manufactured by a process provided herein is provided.
• the liposomal API encapsulation comprises mixing a lipid solution comprising a lipid dissolved in an organic solvent with an aqueous API solution, wherein the lipid solution and aqueous API solution are mixed from two separate streams in an in-line fashion, and wherein a liposomal encapsulated API is formed at the intersection of the two streams.
• the liposomal API encapsulation takes place in a central vessel via an alcohol injection method.
• the method in a first embodiment, comprises introducing a liposomal encapsulated API into a central vessel or forming a liposomal encapsulated API in the central vessel.
• the central vessel comprises a first inlet, a second inlet, a first outlet and a second outlet.
• the liposomal encapsulated API in one embodiment, is introduced through the first inlet of the central vessel.
• the first outlet of the central vessel is in fluid communication with an inlet of a first tangential flow filtration (TFF) unit.
• FFF first tangential flow filtration
• tangential flow filtration unit or“TFF unit” are art-known and mean a device that includes at least one housing (such as a cylinder or cartridge) and at least one cross-flow (tangential) filter positioned in the housing such that a large portion of tire filter’s surface is positioned parallel to the flow of a fluid (e.g, a liposomal suspension) through the unit.
• a TFF unit includes one filter.
• a TFF unit includes two filters.
• the TFF unit includes three filters.
• TFF units are well-known in the art and are commercially available, e.g, from Pall Life Sciences.
• the housing can include a first inlet/outlet and a second inlet/outlet positioned, e.g, to allow fluid to pass through the first inlet/outlet, cross the at least one cross-flow filter, and through the second inlet/outlet.
• a circuit system can include multiple TFF units, e.g., connected in series and/or in parallel .
• TFF units can be connected in series and/or parallel to provide a fluid path of desired length.
• 4, 5, 6, 7, 8, 9 or 10 TFF units can be connected in parallel and/or series in the methods provided herein.
• 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15 TFF units are connected in parallel and/or series in the methods provided herein.
• from about 5 to about 20 or from about 5 to about 15 TFF units are connected in series in one of the methods provided herein
• a circuit system that includes two or more TFF units can include fluid conduits fluidly connecting neighboring pairs of TFF units in the system.
• a circuit system can include two or more TFF units fluidly connected by fluid conduits.
• the TFF unit in one embodiment, is a single pass TFF (SPTFF) unit.
• the two or more TFF units comprise a TFF unit and a SPTFF unit
• the first TFF unit comprises the aforementioned inlet and a first and second outlet.
• Tie first outlet of the first TFF unit is the retentate outlet, and is in fluid communication with the second inlet of the central vessel and the second outlet of the first TFF unit is a waste (permeate) outlet.
• the second outlet of the central vessel is in fluid communication with an inlet of a second TFF unit comprising the inlet and a first and second outlet.
• Tie first outlet of the second TFF unit is a retentate outlet and the second outlet of the second TFF unit is a waste (permeate) outlet.
• the method further comprises continuously flowing the liposomal encapsulated API into the first TFF unit for a first period of time .
• the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the central vessel through the inlet of the second TFF unit for a second period of time and collecting the l iposomal API formulation from the first outlet of the second TFF unit.
• Fluid communication means direct or indirect fluid communication, e.g., directly through a connection port or indirectly through a process unit such as a TFF unit, central vessel, etc.
• the method comprises flowing the liposomal encapsulated API from the central vessel into one or more additional TFF units prior to flowing the liposomal API formulation into the second TFF unit.
• the second TFF unit is a single pass TFF unit (SPTFF).
• SPTFF single pass TFF unit
• Tire method in a second embodiment, comprises introducing a liposomal encapsulated API into a central vessel or forming a liposomal encapsulated API in the central vessel.
• the central vessel comprises an inlet and an outlet.
• the liposomal encapsulated API in one embodiment, is introduced through the inlet of the central vessel.
• the outlet of the central vessel is in fluid communication with an inlet of a first tangential flow filtration (TFF) unit.
• the first TFF unit comprises the aforementioned inlet and a first and second outlet.
• the first outlet of the first TFF unit is in fluid communication with the inlet of a second TFF unit comprising the inlet and a first and second outlet.
• the first outlet of the second TFF unit is a retentate outlet and the second outlet of the second TFF unit is a waste (permeate) outlet.
• Tire method further comprises continuously flowing the liposomal encapsulated API into the first TFF unit for a first period of time.
• the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• Tire method further comprises flowing the liposomal encapsulated API from the first outlet of the first TFF through the inlet of the second TFF unit for a second period of rime and collecting the liposomal API formulation from the first outlet of the second TFF unit.
• the method comprises flowing the liposomal encapsulated API from the central vessel into one or more additional TFF units prior to flowing tire liposomal API formulation into the second TFF unit.
• the second TFF unit is a single pass TFF unit (SPTFF).
• SPTFF single pass TFF unit
• the method comprises introducing the liposomal encapsulated API into a first central vessel or forming the liposomal encapsulated APT in the first central vessel.
• Tire first central vessel comprises a first inlet, a second inlet, a first outlet and a second outlet.
• the liposomal encapsulated API in one embodiment is introduced into the central vessel through the first inlet.
• the first outlet of the first central vessel is in fluid communication with an inlet of a first tangential flow filtration (TFF) unit comprising the inlet and a first and second outlet.
• TMF tangential flow filtration
• the first outlet of the first TFF unit is in fluid communication with the second inlet of the first central vessel and the second outlet of the first TFF unit is a waste (permeate) outlet.
• the second outlet of the first central vessel is in fluid communication with a first inlet of a second central vessel.
• the second central vessel comprises the first inlet, a second inlet, a first outlet and a second outlet.
• the first outlet of the second central vessel is in fluid communication with an inlet of a second tangential flow filtration (TFF) unit comprising the inlet and a first and second outlet.
• the first outlet (retentate outlet) of the second TFF unit is in fluid communication with the second inlet of the second central vessel, the second outlet of the second TFF unit is a waste (permeate) outlet.
• the second outlet of the second central vessel is fluid communication with an inlet of a third TFF unit comprising the inlet and a first and second outlet.
• the first outlet of the third TFF unit is a retentate outlet and the second outlet of the third TFF unit is a waste (permeate) outlet.
• the method further comprises continuously flowing the liposomal encapsulated API into the first TFF unit for a first period of time, wherein the liposomal encapsulated API enters the first TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the first central vessel into the second central vessel for a second period of time and continuously flowing the liposomal encapsulated API into the second TFF unit from the second central vessel for a third period of time.
• the liposomal encapsulated API enters the second TFF unit through the TFF inlet and exits through the first outlet.
• the method further comprises flowing the liposomal encapsulated API from the second central vessel through the inlet of the third TFF unit for a fourth period of time; and collecting the liposomal encapsulated API formulation from the first outlet of the third TFF unit.
• The“first period of time”,“second period of time”,“third period of time” and “fourth period of time” can each be selected by the user of the method, depending in part on the selection of materials used to formulate the liposomal API, and/or the desired concentration of the liposomal API formulation.
• the first period of time”,“second period of time”,“third period of time” and/or“fourth period of time” are each independently 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 fa, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, 96 h or 108 h.
• an initial liposome formation step is employed.
• a variety of liposomal encapsulation methods are available to those of ordinary skill in the art, and can be employed herein .
• the liposomal encapsulation step in one embodiment, is carried out upstream of an initial filtration step.
• the liposomal encapsulation, m one embodiment, takes place in a first central vessel. In another embodim ent, the liposomal encapsul ation takes place upstream of the first central vessel, and is provided to the first central vessel .
• Liposomes were first discovered the early- 1960s and a number of strategies have been demonstrated for their manufacture since (Mozafari. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005, 10(4), 711-719; Maherani et al. Liposomes: A Review of Manufacturing Techniques and Targeting Strategies. Current Nanoscience. 201 1 , 7(3), 436-445; each of which is incorporated by reference herein in its entirety for all purposes).
• liposomal products are reformulations of compendial APIs meant to alleviate adverse clinical side effects and/or provide a more targeted delivery as compared to systemic dosages (Maurer et al. Expert Opinion on Biological Therapy. 2001, 6, 923- 947; Lian and Ho. Expert J Pharm Sci. 2001 , 6, 667-680; each of which is incorporated by reference herein in its entirety for all potposes).
• a liposomal API can be provided to die first central vessel or in the first central vessel via a supercritical fluid method, dense gas method, alcohol injection or crossflow method.
• an alcohol injection or crossflow technique is employed in one of the manufacturing methods provided herein.
• the liposomes are fomied in the first central vessel, e.g., via alcohol injection, or provided to the first central vessel after liposome formulation at an upstream in-line formation step.
• dissolved lipids are precipitated from an organic solvent into an aqueous solution (anti solvent) by means of reciprocal diffusion of the alcohol and aqueous phases ( Figures 1- 2) (Jaafar-Maalej et al. Ethanol injection method for hydrophilic and lipophilic drug- loaded liposome preparation. Journal of Liposome Research. 2010, 20:3, 228-243; Wagner et al. Liposomes produced in a pilot scale: production, purification and efficiency aspects. European Journal of Pharmaceutics and Biopharmaceutics. 2002, 54, 213-219; Wagner et ai.
• the crossflow injection technique An improvement of the ethanol injection method.
• Parameters for the formation of liposomes by this method are residence time and geometry of the mixing/intersection of organic-sol vated lipid and the antisolvent, which are dictated by programmed flow conditions.
• the mixture containing undesired organic solvent and unencapsulated API can then be refined to the desired formulation strength and composition using TFF or similar methods, as set forth herein.
• the present invention provides a method for continuous manufacture of a liposomal product comprising an active pharmaceutical ingredient (API) encapsulated by a liposome, or complexed with a liposome.
• API active pharmaceutical ingredient
• the API is an aminoglycoside.
• the aminoglycoside is amikacin, or a pharmaceutically acceptable sat thereof.
• A“pharmaceutically acceptable salt” includes both acid and base addition salts.
• a pharmaceutically acceptable addition salt refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid (HC1), hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid,
• the pharmaceutically acceptable salt is HC!, TFA, lactate or acetate.
• a pharmaceutically acceptable base addition salt retains the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable.
• These salts are prepared from addition of an inorganic base or an organic base to the free acid.
• Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
• Inorganic salts include the ammonium, sodium, potassium, calcium, and magnesium salts.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triediylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucarnine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, ⁇ -ethylpiperidine, polyamine resins and the like.
• unit operation is a term of art and means a functional step that can be performed in a process of manufacturing a liposomal encapsulated API.
• a unit of operation can be mixing a lipid and API to form a liposomal encapsulated API, filtering (e.g., removal of contaminant bacteria, removal of free API, removal of free lipid, etc., from a fluid containing a liposomal encapsulated API), adjusting the ionic concentration and/or pH of a fluid containing the liposomal encapsulated API, removing unwanted salts.
• the unit operations downstream of liposome formation in the continuous manufacturing processes provided herein are used to refine the liposomal API formulation to the desired specification.
• unit operations such as TFF are used to remove undesired elements, such as non-encapsulated API or organic solvent, and concentrate the liposomal API formulation to a final desired strength.
• the retentate contains the liposomal API formulation and the permeate acts as a waste stream. See, e.g., Figures 3-6 for Examples of processes that can be employed in the methods provided herein .
• TFF for the buffer exchange and concentration in liposomal API formulation manufacturing is balanced to support continuous operation.
• a batch mode design for this operation entails a TFF step where the liposome-containing retentate is returned to the central vessel and the permeate/waste stream is made up with a feed of fresh buffer (constant-weight diafiltration), facilitating the buffer exchange.
• the product is concentrated to the desired strength by ceasing buffer addition ( Figures 1, 2).
• continuous buffer exchange and/or a concurrent concentration step are employed.
• a single vessel buffer exchange TFF system with single stage concurrent concentrating SPTFF serves as one embodiment for a continuous design ( Figure 3). If steady state diafiltration or single pass concentration are not able to achieve the required rate of buffer exchange or concentration with a single stage, additional stages may be added ( Figures 4, 5). Additionally, more compact designs for continuous buffer exchange, such as the CadenceTM In-line Diafiltration Module (ILDF), are becoming available and can be employed in a continuous liposomal manufacturing process provided herein (see, e.g., Gjoka et al. (2017) Platfomi for Integrated Continuous Bioprocessing. BioPharm International.
• ILDF CadenceTM In-line Diafiltration Module
• ILDF design concluding with SPTFF, without wishing to be bound by theory, is thought to eliminate the need for multiple vessels to support continuous buffer exchange (Figure 6).
• the ILDF design in Figure 6 can be modified, e.g., to include additional TFF units in series and/or parallel, for example, an additional, 1, 2, 3, 4, 5 or 6 TFF Units in series and/or parallel.
• additional TFF units in series and/or parallel, for example, an additional, 1, 2, 3, 4, 5 or 6 TFF Units in series and/or parallel.
• Other ILDF system architectures amenable for use with the methods provided herein are found in U.S. Patent Application Publication No. 2017/0225123, the disclosure of which is incorporated by reference herein in its entirety for all purposes.
• Particle size measurements are used to correlate size to concentration of the liposomal API product.
• the continuous manufacturing process is set up using pre-sterilized componentry and/or steam -in-place (SIP) equipment, and the feed solutions (API containing aqueous solution, lipid in organic solvent, or buffer) must enter the system through sterilizing filters containing a pore size of typically 0.2 pm or less.
• the capability (ability of the filter to remove given concentrations of organism) and/or duration (time of use before grow-through of an organism compromises the filter) of the sterile filtration step is validated prior to implementing one or both in the continuous manufacturing methods provided herein.
• a massively redundant filtration design or a sequential use of a parallel filtration pathways is employed. Without wishing to be bound by theory, it is thought that sequential use of parallel pathways is a viable solution since multiple redundant pathways can cause significant pressure drop issues.
• the API encapsulated by the liposomal manufacturing processes provided herein is an antiinfective.
• Antiinfectives are agents that act against infections, such as bacterial, mycobacterial, fungal, viral or protozoal infections
• Antiinfectives that can be hposomally encapsulated by the methods provided herein include but are not limited to aminoglycosides (e.g., streptomycin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and the like), tetracyclines (such as chlortetracycline, oxytetracycline, methacycline, doxycycline, minocycline and the like), sulfonamides (e.g , sulfanilamide, sulfadiazine, suifamethaoxazoie, sulfisoxazole, sulfacetamide, and the like), paraaminobenzoic acid, diaminopyr
• Anthnfectives can include antifungal agents, including polyene antifungals (such as amphotericin B, nystatin, natamycin, and the like), flucytosine, imidazoles (such as n-ticonazole, clotrimazole, econazole, ketoconazole, and the like), triazoles (such as itraconazole, fluconazole, and the like), griseofulvin, terconazole, butoconazole cieiopirax, ciclopirox olamine, haloprogin, tolnaftate, naftifine, terbinafme, or any other antifungal that can be lipid encapsulated or complexed. Discussion and the examples are directed primarily toward amikacin but the scope of the application is not intended to be limited to this antiinfective. Combinations of APIs can be used.
• the API is an aminoglycoside, quinolone, a polyene antifungal or a polymyxins.
• the API is an aminoglycoside.
• the aminoglycoside is an aminoglycoside free base, or its salt, solvate, or other non-covalent derivative.
• the aminoglycoside is amikacin.
• suitable aminoglycosides used in the API formulations of the present invention are pharmaceutically acceptable addition salts and complexes of APIs. In eases where the compounds may have one or more chiral centers, unless specified, the present invention comprises each unique racemic compound, as well as each unique nonracemic compound.
• both the cis (Z) and trans (E) isomers are within the scope of this invention .
• each tautomeric form is contemplated as being included within the invention.
• Amikacin in one embodiment, is present in the pharmaceutical formulation as amikacin base, or amikacin salt, for example, amikacin sulfate or amikacin disulfate.
• a combination of one or more of the above aminoglycosides is used in the formulations, systems and methods described herein. In a further embodiment, the combination comprises amikacin.
• the API is amikacin, or a pharmaceutically acceptable salt thereof.
• the amikacin is amikacin sulfate.
• the API is an aminoglycoside selected from amikacin, apramycin, arbekacin, astromicin, capreomycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodestreptomycin, ribostamycin, sisomicin, spectinomycm, streptomycin, tobramycin, verdamicin, or a combination thereof.
• the API is an aminoglycoside selected from AC4437, amikacin, apramycin, arbekacin, astromicin, bekanamycin, boholmycin, brulamycin, capreomycin, dibekacin, dactimicin, etimicin, framycetin, gentamicin, HI 07, hygromycin, hygromycin B, mosamycin, K-4619, isepamicin, KA-5685, kanamycin, neomycin, netilmicin, paromomycm, plazomicin, ribostamycin, sisomicm, rhodestreptomycin, sorbistin, spectinomycin, sporaricin, streptomycin, tobramycin, verdamicin, vertilmicin, or a combination thereof.
• the API comprises a glycopeptide antibiotic.
• Giycopeptide antibiotics including vancomycin and teicoplanin, are large, rigid molecules that inhibit a late stage in bacterial cell wall peptidoglycan synthesis. Glycopeptides are characterized by a multi-ring peptide core containing six peptide linkages, an unusual triphenyl ether moiety, and sugars attached at various sites. Over 30 antibiotics designated as belonging to the glycopeptide class have been reported. Among the glycopeptides, vancomycin and teicoplanin are used widely and are recommended for treatment of severe infections, especially those caused by multiple-drag-resistant Gram positive pathogens.
• the glycopeptide avoparcin has been introduced as a growth promoter in animal husbandry in the past, and represents the main reservoir for the VanA type of vancomycin resistance in enterococci.
• Semisynthetic derivatives of vancomycin and teicoplanin, lipoglycopeptides showed an extended spectrum of activity against multi-resistant and partly vancomycin-resistant bacteria (Reynolds (1989). Eur. J. Clin Microbiol Infect Dis 8, pp. 943-950; Nordmann et al. (2007). Curr. Opin. Microbiol. 10, pp. 436-440).
• Each of the publications referenced in this paragraph are incorporated by reference herein in their entireties.
• glycopeptide antibiotics are active against Gram-positive organisms and a few anaerobes.
• the main indications for glycopeptide antibiotics are infections caused by beta-lactamase-producing Staphylococcus aureus (for which beta-lactamase-resistant penicillins, cephalosporins, and combinations of penicillins with inhibitors of beta- lactamases proved safer alternatives), and colitis caused by Colstridium difficile.
• MRSA methicillin-resistant S. aureus
• Teicoplanin is comparable to vancomycin in terms of activity, but presents pharmacokinetic advantages, such as prolonged half-life, allowing for a once-daily administration (van Bambeke F., Curr. Opin. Pharm., 4(5):471-478).
• glycopeptides that can be used in the compositions of the present invention are provided in Table 2.
• the antibiotic complexes are listed in alphabetical order along with the structure type producing organism. These metabolites are elaborated by a diverse group of actinomycetes ranging from the more prevalent Streptomyces species to the relatively rare genera of Streptosporangium and Saccharomonospora. The less common Actionplanes and Amycolatopsis account for almost half of the producing organisms (Nagarajan, R., Glycopeptide Antibiotics, CRC Press, 1994, incorporated by reference herein in its entiret ).
• the glycopeptide antibiotic used in the composition of the present invention includes, but is not limited to, A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, Actaplanin, Actinoidin, Ardacin, Avoparcin, Azureomycin, Chloroorienticin Chloropolysporin, Decaplanin, N-demethylvancomycin, Eremomycin, Galacardin, Helvecardin Izupeptin, Kibdelin, LL-AM374, Mannopeptin, MM45289, MM47761, MM47766, MM55266, MM55270, OA-7653, Orienticm, Parvodicin, Ristocetin, Ristomycin, Synmonicin, Teicoplanin, UK-68597, UK-69542, UK-72051, vancomycin, and a mixture thereof.
• the API is vancomycin.
• Vancomycin is a water soluble amphoteric glycopeptide bactericidal antibiotic that inhibits gram-positive bacterial mucopeptide biosynthesis. It consists of a tricyclic nonribosomal heptapeptide core structure to which is attached a disaccharide unit consisting of the aminodeoxy sugar, vancosamine, and D-giucose. This natural antibiotic of -1450 Daltons is obtained from Strepiomyces orientalis (also known as; Nocardia oriental , or Amycolaiopsis orientalTM). Vancomycin has one carboxyl group with pKa 2.18, and two am o groups: primary amine with pKa 7.75 and the secondary amine with pKa 8.89. At sub- physiological pH vancomycin has a net positive charge.
• the API is oritavancin (LY333328).
• Oritavancin is obtained by reductive alkylation with 4’ chloro-biphenyicarboxa!dehyde of the natural glycopeptide chloroeremomycin, which differs from vancomycin by the addition of a 4- epi -vancosamine sugar and the replacement of the vancosamine by a 4-epivancosamine (Cooper, R. et al., I Antibiot (Tokyo) 1996, 49:575-581, incorporated by reference herein in its entirety).
• oritavancin presents a general spectrum of activity comparable to that of vancomycin, it offers considerable advantages m terms of intrinsic activity (especially against streptococci), and remains insensitive to the resistance mechanisms developed by staphylococci and enterococci. Because the binding affinity of vancomycin and oritavancin to free D-Aia-D-Ala and D-Ala-D-Lac are of the same order of magnitude, the difference in their activity has been attributed to the cooperative interactions that can occur between the drug and both types of precursors in situ. The previous study suggested that the effect is caused possibly by a much stronger ability to dimerize and the anchoring in the cytosolic membrane of tire chiorobipheny! side chain (Allen, etal., FEMS Microbiol Rev, 2003, 26:51 1-532, incorporated by reference herein).
• the API is tela ancin (TD-6424).
• Teiavancin is a semi- synthetic derivative of vancomycin, possessing a hydrophobic side chain on the vancosamine sugar (decyiaminoethyl) and a (phosphonomethyl) aminomethyl substituant on the cyclic peptidic core (van Bambeke, F., Curr. Opin. Pharm., 4(5): 471-478: Judice, J. et ah, Bioorg Med Chem Lett 2.003, 13: 4165-4168, incorporated by reference herein in its entirety).
• the length of the hydrophobic side chain was chosen to reach a compromise between optimized activity against MRSA (8- 10 carbons) and Van A enterococci (12- 16 carbons).
• Pharmacological studies suggest that the enhanced activity of telavancin on S. pneumoniae, S. aureus (to a lesser extent), and staphylococci or enterococci harboring the vanA gene cluster results from a complex mechanism of action which, on the basis of data obtained with close analogs, involves a perturbation of lipid synthesis and possibly membrane disruption
• the API is dalbavancin (BI 397).
• Dalbavancin is a semi-synthetic derivative of A40926, a glycopeptide with a structure related to that of teicoplanin.
• oritavancin and telavancin dalbavancin is more active against S. pneumoniae than are conventional glycopeptides, and its activity against A aureus is also substantially improved, which was not observed with the semi-synthetic derivatives of vancomycin.
• studies have shown that it is not more active than teicoplanin against enterococci harboring the VanA phenotype of resistance to glycopeptides.
• Hie lipid component used in the continuous manufacturing process described herein in one embodiment comprises a net neutral lipid, or a combination of net neutral lipids.
• the lipid component is free of anionic lipids.
• the lipid is a phospholipid, including but not limited to, a phosphatidylcholine such as dipalmitoylphosphatidylcholine or dioleoylphosphatidyicholine; a sterol, including, but not limited to, cholesterol; or a combination of a phosphatidylcholine and a sterol (e.g., cholesterol).
• Examples of the lipid component that can be used in preparing the stabilized lipid- based glycopeptide antibiotic composition of the present invention includes, but is limited to, phosphatidylcholine (PC), phosphatidylglyceroi (PG), phosphatidylinositol (PI), phosphatidylserme (PS), phosphatidylethanolamine (PE), phosphatidic acid (PA), egg phosphatidylcholine (EPC), egg phosphatidylglyceroi (EPG), egg phosphatidylinositol (EPI), egg phosphatidylserine (EPS), phosphatidylethanolamine (EPE), phosphatidic acid (EPA), soy phosphatidylcholine (SPC), soy phosphatidylglyceroi (SPG), soy phosphatidylserine (SPS), soy phosphatidylinositol (SPI), soy phosphatid
• the lipid component used in the continuous manufacturing process of the present invention comprises palmitoylstearoylphosphatidylcholine (PSPC), palmitoylstearoylphosphatidylglycerol (PSPG), triacylglycerol, diacylglycerol, seranide, sphingosine, sphingomyelin, a single acylated phospholipid, such as mono-oleoyi-phosphatidylethanol amine (MOPE), or a combination thereof.
• PSPC palmitoylstearoylphosphatidylcholine
• PSPG palmitoylstearoylphosphatidylglycerol
• triacylglycerol diacylglycerol
• diacylglycerol diacylglycerol
• seranide sphingosine
• sphingomyelin a single acylated phospholipid
• MOPE mono-oleoyi-phosphatidyl
• the lipid component used in the continuous manufacturing process comprises an ammonium salt of a fatty acid, a phospholipid, sterol, a phosphatidylglycerols (PG), a phosphatidic acid (PA), a phosphotidylcholine (PC), phosphatidylinositol (PI) or a phosphatidylserine (PS)
• the fatty acid can be a fatty acids of carbon chain lengths of 12 to 26 carbon atoms that is either saturated or unsaturated.
• Some specific examples include, but are not limited to, myristylamine, palmitylamine, laurylamine and stearylamine, dilauroyl ethylphosphocholine (DLEP), dimyristoyl ethylphosphocholine (DMEP), dipalmitoyi ethylphosphocholine (DPEP) and distearoyl ethylphosphocholine (DSEP), N-(2, 3- di-(9 (Z)-octadecenyloxy)-prop-l-yl- N,N,N-trimethylammonium chloride (DOTMA) and 1, 2-bis(oleoyloxy)-3- (trimethylammonio)propane (DOTAP).
• DLEP dilauroyl ethylphosphocholine
• DMEP dimyristoyl ethylphosphocholine
• DPEP dipalmitoyi ethylphosphocholine
• DSEP distearoyl ethylphospho
• tire lipid component comprises a phosphatidylcholine.
• the phosphatidylcholine is dipalmitoylphosphatidylcholme (DPPC) or palmitoyloleoylphosphatidylchohne (POPC).
• the phosphatidylcholine comprises DPPC.
• the lipid component comprises a phosphatidylglycerol.
• the phosphatidylglycerol is 1-palmitoyl- 2-oleoyl-sn-glycero-3-phosphoglycerol (POPG).
• the lipid component comprises a sterol, including, but not limited to, cholesterol and ergosterol.
• the lipid component comprises a phospholipid and a sterol.
• the sterol is cholesterol.
• the lipid-to-API weight ratio of the liposomal encapsulated API provided herein in one embodiment, is 3 to 1 or less, 2.5 to 1 or less, 2 to 1 or less, 1.5 to 1 or less, or 1 to 1 or less.
• the lipid to API ratio of the liposomal encapsulated API provided herein in another embodiment, is less than 3 to 1, less than 2.5 to 1, less than 2 to 1, less than 1.5 to I, or less than 1 to 1.
• the lipid to API ratio is about 0.7 to 1 or less or about 0.7 to 1.
• the API is an aminoglycoside, e.g., amikacin or a pharmaceutically acceptable salt thereof.
• the lipid-to-API weight ratio (lipidAPI) of the liposomal encapsulated API provided herein is from about 3: 1 to about 0.5: 1, from about 2.5: 1 to about 0.5: 1, from about 2: 1 to about 0.5: 1, from about 1.5: 1 to about 0.5: 1, or from about 1 : 1 to about 0.5: 1.
• the API is an aminoglycoside, e.g., amikacin or a pharmaceutically acceptable salt thereof.
• the batch process is able to produce 2500 filled units in 20 hr. of total processing time including preparation (assembly, CIP/SIP, etc.). This calculates to 125 units/hr.
• Hie continuous process with a 24 hr. liposome formation step produces 18,750 filled units in 34 hr. of total process time or 551 units/hr. This translates to a 4.4-fold increase in output for the same overhead costs and a 7 5-fold output increase for the same process preparation costs and singie-use componentry' costs (sterilizing filters, TFF cartridges). This ignores the additional capital expenses needed to achieve one of the continuous designs previously mentioned (e.g , set forth at Figures 3-6).
• This example outlines a continuous inline dialfiltration (ILDF)/concentration of a liposomal amikacin formulation having a lipid component consisting of DPPC and cholesterol.
• This Example is concerned with understanding the operating conditions/parameters for the continuous in-line diafiltration module.
• the equipment and components in Table 3 below was used for both experiments executed under this Example.
• the ILDF setup utilized two standard peristal tic pumps for operations - the first to control the feed and retentate, and the second to control the buffer injection .
• the ILDF included six fluid treatment modules.
• a fluid treatment module comprises a filtration membrane, feed channel and permeate channel (i .e., the diagram shown in Figure 6 with one additional fluid treatment module).
• the Meifi system records flow rates, pressure, temperature, vessel weight and time.
• Amikacin and lipid infusion was carried out via an in-line method to create 2L of a liposomal amikacin suspension, as described in U.S. Patent No. 7,718,189, tire disclosure of which is incorporated by reference herein in its entirety.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=68060775

Family Applications (1)

Country Status (4)

Cited By (2)

Families Citing this family (3)

Citations (8)

Family Cites Families (353)

• 2019
  • 2019-03-29 EP EP19774338.8A patent/EP3773505B1/en active Active
  • 2019-03-29 WO PCT/US2019/024901 patent/WO2019191627A1/en not_active Ceased
  • 2019-03-29 US US16/981,149 patent/US11571386B2/en active Active
  • 2019-03-29 JP JP2020552823A patent/JP7460534B2/ja active Active
• 2022
  • 2022-12-30 US US18/091,492 patent/US12290600B2/en active Active
• 2024
  • 2024-03-21 JP JP2024044407A patent/JP2024073637A/ja active Pending
• 2025
  • 2025-03-27 US US19/092,890 patent/US20250325481A1/en active Pending

Patent Citations (9)

Non-Patent Citations (38)

Also Published As

Similar Documents

Legal Events